Interim Data From TID Trial Are Positive
Source: Streetwise Reports (05/15/2025)
Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit.
read more >
One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis (04/28/2025)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report.
read more >
Cell Pouch Co. Peer Aborts Program Using Like Device
Source: Dr. Douglas Loe (04/03/2025)
The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report.
read more >
Regenerative Medicine Firm OK'd To Advance Trial in T1D
Source: Streetwise Reports (04/03/2025)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says the Data Safety Monitoring Board supports the ongoing evaluation of the biotech's Cell Pouch Bio-hybrid Organ in this indication.
read more >
Clean Tech Co. Achieves Record-Breaking Revenue for Exceptional Growth
Source: Streetwise Reports (04/01/2025)
BioLargo Inc. (BLGO:OTCQX) announced in its annual report that in 2024 it saw record revenues and an increase of 45% over the year before. Read why an expert and an analyst both like this clean technology company's story.
read more >